GlassScriptPhysician profile
Shayne C Stokes
NPI 1225007644
$5,316.06
in general payments reported to CMS, 2019-2025
26 companies · $1,264 in 2025
The $1,264 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $323 · 2022: $1,302 · 2023: $1,280 · 2024: $1,147 · 2025: $1,264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,461 · Honoraria: $175 · Education: $32.00 · Consulting Fee: $23.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,460.77 |
| Honoraria | $175.00 |
| Education | $32.00 |
| Consulting Fee | $23.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $893.10 | 2021-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $711.59 | 2021-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $661.40 | 2021-2025 | Dupixent |
| Grifols USA, LLC | $526.29 | 2021-2025 | Prolastin-C Liquid, Xembify |
| Csl Behring | $497.76 | 2022-2025 | Hizentra, Haegarda |
| Aimmune Therapeutics, INC. | $409.30 | 2021-2024 | |
| Blueprint Medicines Corporation | $307.86 | 2023-2025 | Ayvakit |
| Takeda Pharmaceuticals U.S.A., INC. | $230.74 | 2021-2025 | Glassia, Takhzyro, Hyqvia |
| Genzyme Corporation | $167.44 | 2022-2025 | |
| Mylan Specialty L.P. | $133.63 | 2021-2024 | Yupelri |
| Genentech USA, INC. | $108.18 | 2022-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $81.22 | 2022-2025 | |
| Pharming Healthcare, INC. | $76.92 | 2023-2024 | Ruconest |
| Teva Pharmaceuticals USA, INC. | $72.40 | 2021-2022 | |
| Biocryst US Sales Co., LLC | $70.67 | 2022-2025 | Orladeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ars Pharmaceuticals Operations, INC. | $63.68 | 2025 | Neffy |
| Horizon Therapeutics Plc | $48.26 | 2022-2023 | Actimmune |
| Amgen INC. | $48.07 | 2022-2025 | Tezspire |
| Adma Biomanufacturing LLC | $46.83 | 2021-2023 | |
| Ionis Pharmaceuticals, INC. | $30.59 | 2025 | Dawnzera |
| Verona Pharma, INC. | $27.17 | 2025 | Ohtuvayre |
| Jubilant Hollisterstier LLC | $25.71 | 2025 | |
| Pfizer INC. | $23.12 | 2022 | |
| Lilly USA, LLC | $19.46 | 2025 | Ebglyss |
| Viatris Specialty LLC | $19.09 | 2025 | Yupelri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.58 | 2023 | Spiriva Respimat |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shayne Stokes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.